Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Nicotine stimulates brain reward circuitries, most prominently the mesocorticolimbic dopamine system, and this action is considered critical in establishing and maintaining the tobacco smoking habit. Compounds that attenuate nicotine reward are considered promising therapeutic candidates for tobacco dependence, but many of these agents have other actions that limit their potential utility. Nicotine is also highly noxious, particularly at higher doses, and aversive reactions to nicotine after initial exposure can decrease the likelihood of developing a tobacco habit in many first time smokers. Nevertheless, relatively little is known about the mechanisms of nicotine aversion. The purpose of this review is to present recent new insights into the neurobiological mechanisms that regulate avoidance of nicotine. First, the role of the mesocorticolimbic system, so often associated with nicotine reward, in regulating nicotine aversion is highlighted. Second, genetic variation that modifies noxious responses to nicotine and thereby influences vulnerability to tobacco dependence, in particular variation in the CHRNA5-CHRNA3-CHRNB4 nicotinic acetylcholine receptor (nAChR) subunit gene cluster, will be discussed. Third, the role of the habenular complex in nicotine aversion, primarily medial habenular projections to the interpeduncular nucleus (IPN) but also lateral habenular projections to rostromedial tegmental nucleus (RMTg) and ventral tegmental area (VTA) are reviewed. Forth, brain circuits that are enriched in nAChRs, but whose role in nicotine avoidance has not yet been assessed, will be proposed. Finally, the feasibility of developing novel therapeutic agents for tobacco dependence that act not by blocking nicotine reward but by enhancing nicotine avoidance will be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 21×
“Nicotineinduced increases in glutamatergic transmission in the VTA is thought to occur through actions at both α4β2* and α7 nAChRs, leading to increases in mesoaccumbens dopamine transmission and regulation of nicotine selfadministration behavior (Besson et al., 2012; Gao et al., 2010; Mansvelder and McGehee, 2000; Ma…”
InfluentialInput-specific control of reward and aversion in the ventral tegmental area
Lammel, S., Lim, B. K., Ran, C., Huang, K. W., Betley, M. J., Tye, K. M., Deisseroth, K., & Malenka, R. C. (2012) · Nature · doi:10.1038/nature11527 · Cited by 1,300 · cited 3×
“…preferentially synapse onto dopamine neurons that project to the NAc shell, whereas LHb neurons synapse onto dopamine neurons that project to the medial prefrontal cortex or the rostromedial tegmental nucleus (RMTg), both areas of the brain involved in response suppression (Lammel et al., 2012).”
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., et al. (2008) · Nature · doi:10.1038/nature06885 · Cited by 1,275
Saper, C. B., Chou, T. C., & Elmquist, J. K. (2002) · Neuron · doi:10.1016/s0896-6273(02)00969-8 · Cited by 1,120
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 2×
“Indeed, nicotine-induced activation of a4b2* nAChRs in the VTA increases forebrain dopamine transmission, most prominently in the shell region of the nucleus accumbens (NAc), and this has been shown to contribute to the reinforcing properties of the drug in laboratory animals (Iyaniwura et al., 2001; Nisell et al., 19…”
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 1×
“Varenicline (Chantix) is the only FDA-approved smoking cessation agent that was rationally designed through traditional drug discovery and was developed as an α4β2* nAChR partial agonist (Coe et al., 2005; Dwoskin et al., 2009; Lerman et al., 2007; Reus et al., 2007).”
Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl438 · Cited by 850 · cited 1×
“Variation in this cluster is also associated with vulnerability to many smoking-associated diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer (Bierut et al., 2008; Hung et al., 2008; Saccone et al., 2010; Saccone et al., 2007; Thorgeirsson et al., 2008).”
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829
Guidelines on nicotine dose selection for in vivo research
Matta, S. G., Balfour, D. J., Benowitz, N. L., Boyd, R. T., Buccafusco, J. J., Caggiula, A. R., Craig, C. R., Collins, A. C., Damaj, M. I., Donny, E. C., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0441-0 · Cited by 824
Corrigall, W. A., Coen, K. M., & Adamson, K. L. (1994) · Brain Research · doi:10.1016/0006-8993(94)90401-4 · Cited by 740 · cited 1×
“Pharmacological blockade of 42* nAChRs, or genetic disruption of 2 nAChR subunits, almost invariably decreases nicotine intake in rats and mice (Corrigall et al., 1994; Corrigall et al., 1999; Corrigall et al., 2000; David et al., 2006; Ikemoto et al., 2006b; Kenny et al., 2009a; Maskos et al.,…”
Long-term potentiation of excitatory inputs to brain reward areas by nicotine
Mansvelder, H. D., & McGehee, D. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00042-8 · Cited by 720
Jhou, T. C., Fields, H. L., Baxter, M. G., Saper, C. B., & Holland, P. C. (2009) · Neuron · doi:10.1016/j.neuron.2009.02.001 · Cited by 696
Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior
The ENGAGE Consortium, Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.573 · Cited by 689
Habenular α5 nicotinic receptor subunit signalling controls nicotine intake
Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J., & Kenny, P. J. (2011) · Nature · doi:10.1038/nature09797 · Cited by 663
Self-citationVariants in Nicotinic Receptors and Risk for Nicotine Dependence
Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Grucza, R. A., Xuei, X., Saccone, N. L., Saccone, S. F., Bertelsen, S., Fox, L., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111711 · Cited by 648
Acetylcholine Receptor: An Allosteric Protein
Changeux, J.-P., Devillers-Thiéry, A., & Chemouilli, P. (1984) · Science · doi:10.1126/science.6382611 · Cited by 623
Nicotine amplifies reward-related dopamine signals in striatum
Rice, M. E., & Cragg, S. J. (2004) · Nature Neuroscience · doi:10.1038/nn1244 · Cited by 594 · cited 2×
“Presynaptic nAChRs directly regulate the release of dopamine from dopaminergic terminals (Rice and Cragg, 2004; Zhou et al., 2001), in which a4a5b2 nAChR subtype regulates DA release in the dorsal caudate/putamen and the a4a6b2b3 nAChR is involved in the NAc core (Exley et al.”
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585 · cited 2×
“Presynaptic nAChRs directly regulate the release of dopamine from dopaminergic terminals (Rice and Cragg, 2004; Zhou et al., 2001), in which a4a5b2 nAChR subtype regulates DA release in the dorsal caudate/putamen and the a4a6b2b3 nAChR is involved in the NAc core (Exley et al.”
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Maskos, U., Molles, B. E., Pons, S., Besson, M., Guiard, B. P., Guilloux, J.-P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., et al. (2005) · Nature · doi:10.1038/nature03694 · Cited by 566
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551
Representation of negative motivational value in the primate lateral habenula
Matsumoto, M., & Hikosaka, O. (2009) · Nature Neuroscience · doi:10.1038/nn.2233 · Cited by 547 · cited 2×
“Through these projections, the LHb inhibits the firing of midbrain dopamine neurons directly (via VTA projections) or indirectly (via RMTg projections) (Bromberg-Martin and Hikosaka, 2011; Hikosaka, 2010; Jhou et al., 2009; Lecourtier and Kelly, 2007; Matsumoto and Hikosaka, 2009).”
α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking
Berrettini, W., Yuan, X., Tozzi, F., Song, K., Francks, C., Chilcoat, H., Waterworth, D., Muglia, P., & Mooser, V (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002154 · Cited by 465
Saccone, N. L., Culverhouse, R. C., Schwantes-An, T.-H., Cannon, D. S., Chen, X., Cichon, S., Giegling, I., Han, S., Han, Y., Keskitalo-Vuokko, K., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001053 · Cited by 395
The Status of Disulfiram: A Half of a Century Later
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O'Brien, C. P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222512.25649.08 · Cited by 382 · cited 3×
“…in support groups and extensive physician supervision (Brewer et al., 2000), treatment effectiveness can also be enhanced by concomitant use of other therapeutics, such as acamprosate, a glutamate antagonist, or naltrexone, an opioid receptor antagonist (Mason et al., 2006; Suh et al., 2006).”
Pons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J. M., Changeux, J. P., Maskos, U., & Fratta, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3918-08.2008 · Cited by 312 · cited 1×
“…at both α4β2* and α7 nAChRs, leading to increases in mesoaccumbens dopamine transmission and regulation of nicotine selfadministration behavior (Besson et al., 2012; Gao et al., 2010; Mansvelder and McGehee, 2000; Mao et al., 2011; Melis et al., 2013; Pons et al., 2008; Schilstrom et al., 2000).”
Salas, R., Sturm, R., Boulter, J., & De Biasi, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4934-08.2009 · Cited by 310 · cited 1×
“This system is also involved in the expression of somatic aspects of the nicotine withdrawal syndrome (Salas et al., 2009).”
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · cited 2×
“In the context of developing a4b2a5* nAChR PAMs for smoking cessation, it is interesting to note that the acetylcholinesterase (AChE) inhibitors galantamine and physostigmine are PAMs of a4b2* nAChRs (Maelicke et al., 2001; Pereira et al., 1994, 1993; Samochocki et al., 2003; Samochocki et al., 2000; Storch et al., 19…”
Lecourtier, L., & Kelly, P. H. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.01.004 · Cited by 283
Frahm, S., Ślimak, M. A., Ferrarese, L., Santos-Torres, J., Antolin-Fontes, B., Auer, S., Filkin, S., Pons, S., Fontaine, J.-F., Tsetlin, V., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.013 · Cited by 283
Lateral habenula neurons signal errors in the prediction of reward information
Bromberg-Martin, E. S., & Hikosaka, O. (2011) · Nature Neuroscience · doi:10.1038/nn.2902 · Cited by 275
Weiss, R. B., Baker, T. B., Cannon, D. S., von Niederhausern, A., Dunn, D. M., Matsunami, N., Singh, N. A., Baird, L., Coon, H., McMahon, W. M., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000125 · Cited by 271 · cited 2×
“behavior (Weiss et al., 2008), a self-reported “pleasurable buzz” during smoking (Sherva et al.”
Smoking withdrawal dynamics in unaided quitters.
Piasecki, T. M., Niaura, R., Shadel, W. G., Abrams, D., Goldstein, M., Fiore, M. C., & Baker, T. B. (2000) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.109.1.74 · Cited by 262
Kenny, P. J., & Markou, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300905 · Cited by 261
Self-citationThe subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum
Grady, S. R., Salminen, O., Laverty, D. C., Whiteaker, P., McIntosh, J. M., Collins, A. C., & Marks, M. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.032 · Cited by 252 · cited 2×
“The rewarding actions of nicotine may occur through the a4a6b2b3* nAChR subtype (Grady et al., 2007), which has the highest sensitivity to nicotine of any native nAChR so far identified (Grady et al.”
Grady, S. R., Moretti, M., Zoli, M., Marks, M. J., Zanardi, A., Pucci, L., Clementi, F., & Gotti, C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5121-08.2009 · Cited by 222
Roles of Accessory Subunits in α4β2* Nicotinic Receptors
Kuryatov, A., Onksen, J., & Lindstrom, J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046789 · Cited by 195 · cited 2×
“Intriguingly, a recent study reported that galantamine is a PAM only at α4β2α5* nAChRs, and is practically inactive α4β2* nAChRs that do not contain α5 subunits (Kuryatov et al., 2008).”
Nicotinic Receptor Gene Variants Influence Susceptibility to Heavy Smoking
Stevens, V. L., Bierut, L. J., Talbot, J. T., Wang, J. C., Sun, J., Hinrichs, A. L., Thun, M. J., Goate, A., & Calle, E. E. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0585 · Cited by 190
Does disulfiram have a role in alcoholism treatment today?
FULLER, R. K., & GORDIS, E. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00597.x · Cited by 182 · cited 3×
“The clinical effectiveness of disulfiram has been variable (Brewer et al., 2000; Fuller and Gordis, 2004), most”
Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum
Higley, M. J., Gittis, A. H., Oldenburg, I. A., Balthasar, N., Seal, R. P., Edwards, R. H., Lowell, B. B., Kreitzer, A. C., & Sabatini, B. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019155 · Cited by 175 · cited 2×
“In addition to releasing acetylcholine, these interneurons may also corelease glutamate (Higley et al., 2011).”
A Risk Allele for Nicotine Dependence in CHRNA5 Is a Protective Allele for Cocaine Dependence
Grucza, R. A., Wang, J. C., Stitzel, J. A., Hinrichs, A. L., Saccone, S. F., Saccone, N. L., Bucholz, K. K., Cloninger, C. R., Neuman, R. J., Budde, J. P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.018 · Cited by 152
Ikemoto, S., Qin, M., & Liu, Z.-H. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4542-05.2006 · Cited by 151 · cited 2×
“…of the drug on neuronal nicotinic acetylcholine receptors (nAChRs) containing α4 and β2 subunits (denoted α4β2* nAChRs), particularly those located in the ventral tegmental area (VTA) (Corrigall et al., 1992; Ikemoto et al., 2006a; Maskos et al., 2005; Picciotto et al., 1998; Tapper et al., 2004).”
Sherva, R., Wilhelmsen, K., Pomerleau, C. S., Chasse, S. A., Rice, J. P., Snedecor, S. M., Bierut, L. J., Neuman, R. J., & Pomerleau, O. F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02279.x · Cited by 143
Rada, P., Jensen, K., & Hoebel, B. (2001) · Psychopharmacology · doi:10.1007/s002130100781 · Cited by 141
Mao, D., Perry, D. C., Yasuda, R. P., Wolfe, B. B., & Kellar, K. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05011.x · Cited by 133
Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors
Girod, R., Barazangi, N., McGehee, D., & Role, L. W. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00145-3 · Cited by 122
Laviolette, S. R., & van der Kooy, D. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1317-6 · Cited by 113
κ-Opioid Receptors within the Nucleus Accumbens Shell Mediate Pair Bond Maintenance
Resendez, S. L., Kuhnmuench, M., Krzywosinski, T., & Aragona, B. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5779-11.2012 · Cited by 110 · cited 6×
“…and acetylcholine, opioid signaling also appears to be an important mediator of aversive processing within the NAc, most notably through the kappa opioid receptor (KOR) (McCutcheon et al., 2012; Resendez et al., 2012), and interactions between nicotinic and KOR signaling have been established.”
InfluentialPerry, D. C., Mao, D., Gold, A. B., McIntosh, J. M., Pezzullo, J. C., & Kellar, K. J. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121228 · Cited by 106 · cited 2×
“However, in the mammalian brain it appears that α5 subunits predominantly assembles into α42* nAChR subtypes (Gotti et al., 2007; Kuryatov et al., 2008; Mao et al., 2008; Perry et al., 2007).”
Gao, M., Jin, Y., Yang, K., Zhang, D., Lukas, R. J., & Wu, J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1943-10.2010 · Cited by 99 · cited 2×
“…at both α4β2* and α7 nAChRs, leading to increases in mesoaccumbens dopamine transmission and regulation of nicotine selfadministration behavior (Besson et al., 2012; Gao et al., 2010; Mansvelder and McGehee, 2000; Mao et al., 2011; Melis et al., 2013; Pons et al., 2008; Schilstrom et al., 2000).”
Sartor, C. E., Lessov-Schlaggar, C. N., Scherrer, J. F., Bucholz, K. K., Madden, P. A. F., Pergadia, M. L., Grant, J. D., Jacob, T., & Xian, H. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2010.03.004 · Cited by 93 · cited 1×
“These aversive reactions to nicotine are important in the context of tobacco dependence, as stronger aversive reactions to nicotine after initial exposure are negatively correlated with the development of habitual tobacco use in first time smokers (Sartor et al., 2010).”
Does disulfiram help to prevent relapse in alcohol abuse?
Brewer, C., Meyers, R. J., & Johnsen, J. (2000) · CNS Drugs · doi:10.2165/00023210-200014050-00001 · Cited by 92 · cited 3×
“The clinical effectiveness of disulfiram has been variable (Brewer et al., 2000; Fuller and Gordis, 2004), most”
David, V., Besson, M., Changeux, J.-P., Granon, S., & Cazala, P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.02.003 · Cited by 87 · cited 2×
“Pharmacological blockade of a4b2* nAChRs, or genetic disruption of b2 nAChR subunits, almost invariably decreases nicotine intake in rats and mice (Corrigall et al., 1994, 1999, 2000; David et al., 2006; Ikemoto et al., 2006b; Kenny et al., 2009a; Maskos et al., 2005; Molles et al., 2006).”
Sheffield, E. B., Quick, M. W., & Lester, R. A. J. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00138-6 · Cited by 87
Schoedel, K. A., Sellers, E. M., Palmour, R., & Tyndale, R. F. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.96 · Cited by 64 · cited 2×
“, 2005), and nicotine appears to reduce CYP2A6 transcript and protein levels in monkeys (Ferguson et al., 2012; Schoedel et al., 2003).”
Iyaniwura, T., Wright, A., & Balfour, D. (2001) · Psychopharmacology · doi:10.1007/s002130100852 · Cited by 57 · cited 2×
“Indeed, nicotine-induced activation of a4b2* nAChRs in the VTA increases forebrain dopamine transmission, most prominently in the shell region of the nucleus accumbens (NAc), and this has been shown to contribute to the reinforcing properties of the drug in laboratory animals (Iyaniwura et al., 2001; Nisell et al., 19…”
Cited by
GLP-1 acts on habenular avoidance circuits to control nicotine intake
Tuesta, L. M., Chen, Z., Duncan, A., Fowler, C. D., Ishikawa, M., Lee, B. R., Liu, X.-A., Lu, Q., Cameron, M., Hayes, M. R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4540 · Cited by 200
Self-citationThe lateral habenula in addiction and depression: an anatomical, synaptic and behavioral overview
Lecca, S., Meye, F. J., & Mameli, M. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12480 · Cited by 196
“For instance, a role of the LHb in nicotine addiction has been hypothesized, although currently there is only evidence linking the medial habenula to nicotine addiction (Baldwin et al., 2011; Fowler & Kenny, 2013).”
BackgroundMechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Habenular TCF7L2 links nicotine addiction to diabetes
Duncan, A., Heyer, M. P., Ishikawa, M., Caligiuri, S. P. B., Liu, X.-A., Chen, Z., Micioni Di Bonaventura, M. V., Elayouby, K. S., Ables, J. L., Howe, W. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1653-x · Cited by 119
Self-citationThe CHRNA5–A3–B4 Gene Cluster and Smoking: From Discovery to Therapeutics
Lassi, G., Taylor, A. E., Timpson, N. J., Kenny, P. J., Mather, R. J., Eisen, T., & Munafò, M. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.10.005 · Cited by 85
Self-citation
Metadata
- Authors
- Fowler, C. D., & Kenny, P. J.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 76
- Pages
- 533-544
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1993516763
- Cited by
- 169
- References
- 57
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.